Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: A review

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 2295-2316

  Caetano, Liliana Aranha ^a,b   Almeida, António José ^a   Diogo Gonçalves, Lídia Maria ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

Author keywords

Adjuvants; Microparticles; Mucosal immunity; Nanoparticles; Tuberculosis vaccines; Vaccine delivery systems

Indexed keywords

NANOPARTICLES; VIRUSES;

ADJUVANTS; MICRO AND NANO-PARTICLE; MICRO-PARTICLES; MUCOSAL IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENIC BACTERIUM; PROTECTIVE IMMUNITIES; VACCINE DELIVERY SYSTEM;

VACCINES;

ANTIGEN; BCG VACCINE; CHITOSAN; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; VACCINE;

BCG VACCINATION; DISEASE ERADICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; IMMUNITY; IMMUNOLOGY; MUCOSA; PARTICLE SIZE; PROCEDURES; TUBERCULOSIS; VACCINATION;

ANIMALS; HUMANS; IMMUNITY; MUCOUS MEMBRANE; NANOPARTICLES; PARTICLE SIZE; TUBERCULOSIS; VACCINATION; VACCINES;

EID: 84904861390     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1984     Document Type: Review

References (229)

1. World Health Organization, Global Tuberculosis report 2013, World Health Organization, Geneva (2013).
2. A. M. Cooper, Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393 (2009).
3. K. Lönnroth, K. G. Castro, J. M. Chakaya, L. S. Chauhan, K. Floyd, P. Glaziou, and M. C. Raviglione, Tuberculosis control and elimination 2010-50: Cure, care, and social development. Lancet The 375, 1814 (2010).
4. M. Jassal and W. R. Bishai, Extensively drug-resistant tuberculosis. Lancet Infect. Dis. 9, 19 (2009).
5. World Health Organization, Tuberculosis global facts 2010/2011, World Health Organization, Geneva (2010).
6. S. H. E. Kaufmann, Future vaccination strategies against tuberculosis: Thinking outside the box. Immunity 33, 567 (2010).
7. A. R. Foxwell, J. M. Kyd, and A. W. Cripps, Mucosal immunization against respiratory bacterial pathogens. Expert Rev. Vaccines 2, 551 (2003).
8. R. Reljic, A. Williams, and J. Ivanyi, Mucosal immunotherapy of tuberculosis: Is there a value in passive IgA? Tuberculosis 86, 179 (2006).
9. W. Li, G. Deng, M. Li, X. Liu, and Y. Wang, Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection. Tuberc. Res. Treat. 2012, 791 (2012).
10. E. Torrado, R. T. Robinson, and A. M. Cooper, Cellular response to mycobacteria: Balancing protection and pathology. Trends Immunol. 32, 66 (2011).
11. S. B. Sable, M. Cheruvu, S. Nandakumar, S. Sharma, K. Bandyopadhyay, K. L. Kellar, J. E. Posey, B. B. Plikaytis, R. R. Amara, and T. M. Shinnick, Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One 6, e22718 (2011).
12. P. K. Giri, I. Verma, and G. K. Khuller, Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect. 53, 350 (2006).
13. J. Dietrich, C. Andersen, R. Rappuoli, T. Mark, T. M. Doherty, C. G. Jensen, and P. Andersen, Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior Bacillus Calmette-Guérin immunity. J.Immunol. 177, 6353 (2010).
14. J. Wang, L. Thorson, R. W. Stokes, K. Huygen, A. Zganiacz, M. Hitt, M. Santosuosso, and Z. Xing, Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357 (2004).
15. M. R. Neutra and P. A. Kozlowski, Mucosal vaccines: The promise and the challenge. Nat. Rev. Immunol. 6, 148 (2006).
16. T. H. M. Ottenhoff and S. H. E. Kaufmann, Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog. 8, e1002607 (2012).
17. P. K. Giri and G. K. Khuller, Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev. Vaccines 7, 1341 (2008).
18. G. R. Stewart, B. D. Robertson, and D. B. Young, Tuberculosis: A problem with persistence. Nat. Rev. Microbiol. 1, 97 (2003).
19. J. L. Flynn, Immunology of tuberculosis and implications in vaccine development. Tuberculosis 84, 93 (2004).
20. F. Winau, G. Hegasy, S. H. E. Kaufmann, and U. E. Schaible, No life without death-apoptosis as prerequisite for T cell activation. Apoptosis 10, 707 (2005).
21. D. S. Korbel, B. E. Schneider, and U. E. Schaible, Innate immunity in tuberculosis: Myths and truth. Microbes Infect. 10, 995 (2008).
22. M. Divangahi, D. Desjardins, C. Nunes-Alves, H. G. Remold, and S. M. Behar, Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 11, 751 (2010).
23. J. L. Flynn, J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom, An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249 (1993).
24. J. Flynn, Tumor necrosis factor-? is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561 (1995).
25. A. M. Cooper, L. B. Adams, D. K. Dalton, R. Appelberg, and S. Ehlers, IFN-gamma and NO in mycobacterial disease: New jobs for old hands. Trends Microbiol. 10, 221 (2002).
26. E. L. Corbett, HIV and tuberculosis: Surveillance revisited. Int. J. Tuberc. Lung Dis. 7, 709 (2003).
27. J. Harris and J. Keane, How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161, 1 (2010).
28. M. V Tullius, G. Harth, S. Maslesa-Galic, B. J. Dillon, and M. A. Horwitz, A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect. Immun. 76, 5200 (2008).
29. A. J. Wolf, L. Desvignes, B. Linas, N. Banaiee, T. Tamura, K. Takatsu, and J. D. Ernst, Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205, 105 (2008).
30. V. Lazarevic, D. Nolt, and J. L. Flynn, Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J. Immunol. 175, 1107 (2005).
31. S. T. Reece and S. H. E. Kaufmann, Floating between the poles of pathology and protection: Can we pin down the granuloma in tuberculosis? Curr. Opin. Microbiol. 15, 63 (2012).
32. D. G. Russell, Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5, 39 (2007).
33. L. Jordao, C. K. E. Bleck, L. Mayorga, G. Griffiths, and E. Anes, On the killing of mycobacteria by macrophages. Cell. Microbiol. 10, 529 (2008).
34. M. G. Gutierrez, B. B. Mishra, L. Jordao, E. Elliott, E. Anes, and G. Griffiths, NF-kB activation controls phagolysosome fusion-mediated killing of mycobacteria by macrophages. J. Immunol. 181, 2651 (2008).
35. M. G. Gutierrez, S. S. Master, S. B. Singh, G. a Taylor, M. I. Colombo, and V. Deretic, Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753 (2004).
36. S. B. Singh, A. S. Davis, G. A. Taylor, and V. Deretic, Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science, 313, 1438 (2006).
37. I. Vergne, J. Chua, S. B. Singh, and V. Deretic, Cell biology of Mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 20, 67 (2004).
38. S. H. Kaufmann, How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20 (2001).
39. S. M. Behar, M. Divangahi, and H. G. Remold, Evasion of innate immunity by Mycobacterium tuberculosis: Is death an exit strategy? Nat. Rev. Microbiol. 8, 668 (2010).
40. S. M. Behar, C. J. Martin, M. G. Booty, T. Nishimura, X. Zhao, H.-X. Gan, M. Divangahi, and H. G. Remold, Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 4, 279 (2011).
41. N. Van Der Wel, D. Hava, D. Houben, D. Fluitsma, M. Van Zon, J. Pierson, M. Brenner, and P. J. Peters, M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287 (2007).
42. L. Jordao and O. V Vieira, Tuberculosis: New aspects of an old disease. Int. J. Cell Biol. 2011, 403623 (2011).
43. S. H. Kaufmann and J. Hess, Immune response against Mycobacterium tuberculosis: Implications for vaccine development. J. Biotechnol. 83, 13 (2000).
44. D. G. Russell, H. C. Mwandumba, and E. E. Rhoades, Mycobacterium and the coat of many lipids. J. Cell Biol. 158, 421 (2002).
45. A. M. Aguirre-Blanco, P. T. Lukey, J. M. Cliff, and H. M. Dockrell, Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro. Infect. Immun. 75, 3197 (2007).
46. M. E. Wilson, H. V Fineberg, and G. A. Colditz, Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin. Infect. Dis. 20, 982 (1995).
47. L. Brandt, J. Feino Cunha, A. Weinreich Olsen, B. Chilima, P. Hirsch, R. Appelberg, and P. Andersen, Failure of the Mycobacterium bovis BCG vaccine: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70, 672 (2002).
48. R. E. Weir, G. F. Black, B. Nazareth, S. Floyd, S. Stenson, C. Stanley, K. Branson, L. Sichali, S. D. Chaguluka, L. Donovan, A. C. Crampin, P. E. M. Fine, and H. M. Dockrell, The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi. Clin. Exp. Immunol. 146, 390 (2006).
49. P. Azzopardi, C. M. Bennett, S. M. Graham, and T. Duke, Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: A systematic review. Int. J. Tuberc. Lung Dis. 13, 1331 (2009).
50. M. Hatherill, V. Adams, J. Hughes, M. De Kock, W. Mavakla, B. Pienaar, H. Mahomed, G. Hussey, and W. A. Hanekom, The potential impact of helminth infection on trials of novel tuberculosis vaccines. Vaccine 27, 4743 (2009).
51. L. C. Rodrigues, S. M. Pereira, S. S. Cunha, B. Genser, M. Y. Ichihara, S. C. De Brito, M. A. Hijjar, I. Dourado, A. A. Cruz, C. Sant'Anna, A. L. Bierrenbach, and M. L. Barreto, Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: The BCG-REVAC cluster-randomised trial. Lancet 366, 1290 (2005).
52. N. Dalmia and A. J. Ramsay, Prime-boost approaches to tuberculosis vaccine development. Expert Rev. Vaccines 11, 1221 (2012).
53. D. G. Russell, C. E. Barry, and J. L. Flynn, Tuberculosis: What we don't know can, and does, hurt us. Science 328, 852 (2010).
54. World Health Organization, Tuberculosis vaccine pipeline-2010, Geneva (2010).
55. M. D. Tameris, M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, H. Mahomed, and H. McShane, Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381, 1021 (2013).
56. J. T. van Dissel, S. M. Arend, C. Prins, P. Bang, P. N. Tingskov, K. Lingnau, J. Nouta, M. R. Klein, I. Rosenkrands, T. H. M. Ottenhoff, I. Kromann, T. M. Doherty, and P. Andersen, Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 28, 3571 (2010).
57. R. Rowland and H. McShane, Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10, 645 (2011).
58. D. F. Hoft, A. Blazevic, G. Abate, W. a Hanekom, G. Kaplan, J. H. Soler, F. Weichold, L. Geiter, J. C. Sadoff, and M. a Horwitz, A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 198, 1491 (2008).
59. L. Grode, P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A. N. Eddine, P. Mann, C. Goosmann, S. Bandermann, D. Smith, G. J. Bancroft, J. Reyrat, D. Van Soolingen, B. Raupach, and S. H. E. Kaufmann, Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472 (2005).
60. S. Sadagopal, M. Braunstein, C. C. Hager, J. Wei, A. K. Daniel, M. R. Bochan, I. Crozier, N. E. Smith, H. O. Gates, L. Barnett, L. Van Kaer, J. O. Price, T. S. Blackwell, S. A. Kalams, and D. S. Kernodle, Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. PLoS One 4, e5531 (2009).
61. A. C. Hesseling, H. Rabie, B. J. Marais, M. Manders, M. Lips, H. S. Schaaf, R. P. Gie, M. F. Cotton, P. D. van Helden, R. M. Warren, and N. Beyers, Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42, 548 (2006).
62. M. O. C. Ota, J. Vekemans, S. E. Schlegel-Haueter, K. Fielding, M. Sanneh, M. Kidd, M. J. Newport, P. Aaby, H. Whittle, P.-H. Lambert, K. P. W. J. McAdam, C.-A. Siegrist, and A. Marchant, Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919 (2002).
63. D. E. Dorer, W. Czepluch, M. R. Lambeth, A. C. Dunn, C. Reitinger, F. E. Aldwell, and A. D. McLellan, Lymphatic tracing and T cell responses following oral vaccination with live Mycobacterium bovis (BCG). Cell. Microbiol. 9, 544 (2007).
64. W. Bishai, Z. Sullivan, B. R. Bloom, and P. Andersen, Bettering BCG: A tough task for a TB vaccine? Nat. Med. 19, 410 (2013).
65. S. M. Fortune and E. J. Rubin, The complex relationship between mycobacteria and macrophages: It's not all bliss. Cell Host Microbe 2, 5 (2007).
66. S. D. Schuck, H. Mueller, F. Kunitz, A. Neher, H. Hoffmann, K. L. C. M. Franken, D. Repsilber, T. H. M. Ottenhoff, S. H. E. Kaufmann, and M. Jacobsen, Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS One 4, e5590 (2009).
67. J.-P. Amorij, G. F. a Kersten, V. Saluja, W. F. Tonnis, W. L. J. Hinrichs, B. Slütter, S. M. Bal, J. a Bouwstra, A. Huckriede, and W. Jiskoot, Towards tailored vaccine delivery: Needs, challenges and perspectives. J. Control Release 161, 363 (2012).
68. G. Dietrich, M. Griot-Wenk, I. C. Metcalfe, A. B. Lang, and J.-F. Viret, Experience with registered mucosal vaccines. Vaccine 21, 678 (2003).
69. J. Holmgren and C. Czerkinsky, Mucosal immunity and vaccines. Nat. Med. 11, S45 (2005).
70. P. Brandtzaeg, H. Kiyono, R. Pabst, and M. W. Russell, Terminology: Nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 1, 31 (2008).
71. M. C. Rebelatto, P. Guimond, T. L. Bowersock, and H. HogenEsch, Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet. Immunol. Immunopathol. 83, 93 (2001).
72. G. Mutwiri, T. Bowersock, A. Kidane, M. Sanchez, V. Gerdts, L. A. Babiuk, and P. Griebel, Induction of mucosal immune responses following enteric immunization with antigen delivered in alginate microspheres. Vet. Immunol. Immunopathol. 87, 269 (2002).
73. N. P. Goonetilleke, H. Mcshane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. S. Hill, Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602 (2003).
74. O. Borges, F. Lebre, D. Bento, G. Borchard, and H. E. Junginger, Mucosal vaccines: Recent progress in understanding the natural barriers. Pharm. Res. 27, 211 (2010).
75. G. Källenius, A. Pawlowski, P. Brandtzaeg, and S. Svenson, Should a new tuberculosis vaccine be administered intranasally? Tuberculosis 87, 257 (2007).
76. P. Brandtzaeg, Mucosal immunity: Induction, dissemination, and effector functions. Scand. J. Immunol. 70, 505 (2009).
77. J. R. McGhee, J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono, The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10, 75 (1992).
78. M. E. Lamm, Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51, 311 (1997).
79. C. Czerkinsky, F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. P. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. B. Sun, Mucosal immunity and tolerance: Relevance to vaccine development. Immunol. Rev. 170, 197 (1999).
80. F. W. van Ginkel, H. H. Nguyen, and J. R. McGhee, Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis. 6, 123 (2000).
81. P. Brandtzaeg, Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol. 293, 3 (2003).
82. B. Corthésy, Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol. 5, 817 (2010).
83. V. Pavot, N. Rochereau, C. Genin, B. Verrier, and S. Paul, New insights in mucosal vaccine development. Vaccine 30, 142 (2012).
84. S. Y. Foo and S. Phipps, Regulation of inducible BALT formation and contribution to immunity and pathology. Mucosal Immunol. 3, 537 (2010).
85. S. Mitragotri, Immunization without needles. Nat. Rev. Immunol. 5, 905 (2005).
86. P. Brandtzaeg, Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25, 5467 (2007).
87. J. F. S. Mann, R. Acevedo, J. Del Campo, O. Pérez, and V. A. Ferro, Delivery systems: A vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8, 103 (2009).
88. J. Holmgren, Mucosal immunity and vaccination. FEMS Immunol. Med. Microbiol. 4, 1 (1991).
89. J. Mestecky, M. W. Russell, and C. O. Elson, Perspectives on mucosal vaccines: Is mucosal tolerance a barrier? J. Immunol. 179, 5633 (2007).
90. W. W. J. Unger and Y. van Kooyk, Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Curr. Opin. Immunol. 23, 131 (2011).
91. P. Brandtzaeg, Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 39, 303 (2010).
92. D. C. Otczyk and A. W. Cripps, Mucosal immunization: A realistic alternative. Hum. Vaccin. 6, 978 (2010).
93. A. J. Almeida and H. O. Alpar, Nasal delivery of vaccines. J. Drug Target. 3, 455 (1996).
94. M. Vajdy and M. Singh, The role of adjuvants in the development of mucosal vaccines. Expert Opin. Biol. Ther. 5, 953 (2005).
95. D. Mohanan, B. Slütter, M. Henriksen-Lacey, W. Jiskoot, J. A. Bouwstra, Y. Perrie, T. M. Kündig, B. Gander, and P. Johansen, Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J. Control Release 147, 342 (2010).
96. E. J. Ryan, L. M. Daly, and K. H. Mills, Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19, 293 (2001).
97. R. Medzhitov and C. Janeway, Innate immunity: The virtues of a nonclonal system of recognition. Cell 91, 295 (1997).
98. R. Medzhitov and C. Janeway, Innate immunity. N. Engl. J. Med. 343, 338 (2000).
99. A. Ozinsky, D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem, The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. USA 97, 13766 (2000).
100. G. Diamond, D. Legarda, and L. K. Ryan, The innate immune response of the respiratory epithelium. Immunol. Rev. 173, 27 (2000).
101. D. Parker and A. Prince, Innate immunity in the respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 45, 189 (2011).
102. Y. Fujkuyama, D. Tokuhara, K. Kataoka, R. S. Gilbert, J. R. McGhee, Y. Yuki, H. Kiyono, and K. Fujihashi, Novel vaccine development strategies for inducing mucosal immunity. Expert Rev. Vaccines 11, 367 (2012).
103. M. Singh, M. Ugozzoli, J. Kazzaz, J. Chesko, E. Soenawan, D. Mannucci, F. Titta, M. Contorni, G. Volpini, G. Del, D. T. O. Hagan, G. Del Guidice, and D. T. O'Hagan, A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24, 1680 (2006).
104. K. Eriksson and J. Holmgren, Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 14, 666 (2002).
105. M. Pizza, M. M. Giuliani, M. R. Fontana, E. Monaci, G. Douce, G. Dougan, K. H. G. Mills, R. Rappuoli, and G. Del Giudice, Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534 (2001).
106. K. L. Kotloff, M. B. Sztein, S. S. Wasserman, G. A. Losonsky, S. C. DiLorenzo, and R. I. Walker, Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69, 3581 (2001).
107. N. Lycke, From toxin to adjuvant: Basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol. Lett. 97, 193 (2005).
108. I. Stephenson, M. C. Zambon, A. Rudin, A. Colegate, A. Podda, R. Bugarini, G. Del Giudice, A. Minutello, S. Bonnington, J. Holmgren, K. H. G. Mills, and K. G. Nicholson, Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80, 4962 (2006).
109. J. A. Lapa, S. A. Sincock, M. Ananthakrishnan, C. K. Porter, F. J. Cassels, C. Brinkley, E. R. Hall, J. van Hamont, J. D. Gramling, C. M. Carpenter, S. Baqar, and D. R. Tribble, Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin. Vaccine Immunol. 15, 1222 (2008).
110. S. Jain, K. Khomane, A. K. Jain, and P. Dani, Nanocarriers for transmucosal vaccine delivery. Curr. Nanosci. 7, 160 (2011).
111. A. J. Almeida and H. F. Florindo, Nanocarriers overcoming the nasal barriers: Physiological considerations and mechanistic issues, Nanostructured Biomaterials for Overcoming Biological Barriers, edited by M. J. Alonso and N. S. Csaba, Royal Society of Chemistry, Wakefield, United Kingdom (2012), pp. 117-133.
112. V. W. Bramwell and Y. Perrie, Particulate delivery systems for vaccines: What can we expect? J. Pharm. Pharmacol. 58, 717 (2006).
113. A. F. Azevedo, J. Galhardas, A. Cunha, P. Cruz, L. M. D. Gonçalves, and A. J. Almeida, Microencapsulation of Streptococcus equi antigens in biodegradable microspheres and preliminary immunisation studies. Eur. J. Pharm. Biopharm. 64, 131 (2006).
114. T. Storni, T. M. Kündig, G. Senti, and P. Johansen, Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57, 333 (2005).
115. D. T. O. Hagan, Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34, 305 (1998).
116. M. Vajdy and D. T. O'Hagan, Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. 51, 127 (2001).
117. M. Singh, A. Chakrapani, and D. O'Hagan, Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6, 797 (2007).
118. M. Amidi, E. Mastrobattista, W. Jiskoot, and W. E. Hennink, Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 62, 59 (2010).
119. D. T. O'Hagan and R. Rappuoli, Novel approaches to pediatric vaccine delivery. Adv. Drug Deliv. Rev. 58, 29 (2006).
120. I. M. Van Der Lubben, G. Kersten, M. M. Fretz, C. Beuvery, J. C. Verhoef, and H. E. Junginger, Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine 21, 1400 (2003).
121. C. Keijzer, B. Slütter, R. van der Zee, W. Jiskoot, W. van Eden, and F. Broere, PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 6, e26684 (2011).
122. M. Bivas-Benita, M. Y. Lin, S. M. Bal, K. E. van Meijgaarden, K. L. M. C. Franken, A. H. Friggen, H. E. Junginger, G. Borchard, M. R. Klein, and T. H. M. Ottenhoff, Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27, 4010 (2009).
123. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, PLGA-based nanoparticles: An overview of biomedical applications. J. Control Release 161, 505 (2012).
124. D. Pawar, A. K. Goyal, S. Mangal, N. Mishra, B. Vaidya, S. Tiwari, A. K. Jain, and S. P. Vyas, Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J. 12, 130 (2010).
125. J. Szlȩk, A. Pacławski, R. Lau, R. Jachowicz, and A. Mendyk, Heuristic modeling of macromolecule release from PLGA microspheres. Int. J. Nanomedicine 8, 4601 (2013).
126. B. Slütter, S. Bal, C. Keijzer, R. Mallants, N. Hagenaars, I. Que, E. Kaijzel, W. van Eden, P. Augustijns, C. Löwik, J. Bouwstra, F. Broere, and W. Jiskoot, Nasal vaccination with N -trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28, 6282 (2010).
127. E. Mata, M. Igartua, M. E. Patarroyo, J. L. Pedraz, and R. M. Hernández, Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur. J. Pharm. Sci. 44, 32 (2011).
128. R. Da Costa Martins, J. M. Irache, J. M. Blasco, M. P. Muñoz, C. M. Marín, M. Jesús Grilló M. Jesús De Miguel, M. Barberán, and C. Gamazo, Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 28, 3038 (2010).
129. H. F. Florindo, S. Pandit, L. Lacerda, L. M. D. Gonçalves, H. O. Alpar, and A. J. Almeida, The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone- based nanoparticles. Biomaterials 30, 879 (2009).
130. M. A. Suckow, L. Siger, T. L. Bowersock, J. J. Turek, D. Van Horne, D. Borie, A. Taylor, H. Park, and K. Park, Alginate microparticles for vaccine delivery, Polysaccharide Applications, edited by M. A. El-Nokaly and H. A. Soini, American Chemical Society, Washington, DC (1999), Vol. 737, pp. 1-14.
131. L. A. Caetano, L. Figueiredo, A. J. Almeida, and L. M. D. Gonçalves, Alginate-chitosan particulate delivery systems for mucosal immunization against tuberculosis, Bioengineering (ENBENG), 2012 IEEE 2nd Portuguese Meeting in, Coimbra, Portugal (2012), Vol. I.I, p. 2.
132. W. R. Gombotz and S. F. Wee, Protein release from alginate matrices. Adv. Drug Deliv. Rev. 64, 194 (2012).
133. F. Dobakhti, S. Ajdary, M. Taghikhani, S. Rafiei, K. Bayati, and M. Rafiee-Tehrani, Immune response following oral immunization with BCG encapsulated in alginate microspheres. Iran. J. Immunol. 3, 114 (2006).
134. S. Ajdary, F. Dobakhti, M. Taghikhani, F. Riazi-Rad, S. Rafiei, and M. Rafiee-Tehrani, Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine 25, 4595 (2007).
135. M. Tafaghodi, S. A. Sajadi Tabassi, and M. R. Jaafari, Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int. J. Pharm. 319, 37 (2006).
136. X. Li, X. Kong, S. Shi, X. Zheng, G. Guo, Y. Wei, and Z. Qian, Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol. 8, 89 (2008).
137. F. Dobakhti, T. Naghibi, M. Taghikhani, S. Ajdary, A. Rafinejad, K. Bayati, S. Rafiei, and M. Rafiee-Tehrani, Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice. Microbes Infect. 11, 296 (2009).
138. F. Ghasemi, Study of oral BCG encapsulated in alginate microsphere to prepare DNA vaccine. Clin. Biochem. 44, S163 (2011).
139. M. Tafaghodi, M. Eskandari, A. Khamesipour, and M. R. Jaafari, Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp. Parasitol. 129, 107 (2011).
140. O. Borges, M. Silva, A. de Sousa, G. Borchard, H. E. Junginger, and A. Cordeiro-da-Silva, Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol. 8, 1773 (2008).
141. H. F. Florindo, S. Pandit, L. M. D. Gonçalves, H. O. Alpar, and A. J. Almeida, Streptococcus equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 26, 4168 (2008).
142. H. C. Arca, M. Günbeyaz, and S. Senel, Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8, 937 (2009).
143. F. Esmaeili, S. Heuking, H. E. Junginger, and G. Borchard, Progress in chitosan-based vaccine delivery systems. J. Drug Deliv. Sci. Technol. 20, 53 (2010).
144. I. M. van der Lubben, J. C. Verhoef, G. Borchard, and H. E. Junginger, Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14, 201 (2001).
145. M. Bivas-Benita, K. E. van Meijgaarden, K. L. M. C. Franken, H. E. Junginger, G. Borchard, T. H. M. Ottenhoff, and A. Geluk, Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A&z.ast;0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22, 1609 (2004).
146. L. A. Caetano, R. Amaral, L. Figueiredo, A. J. Almeida, and L. M. D. Goncalves, Chitosan-alginate microparticulate delivery system for an alternative route of administration of BCG vaccine, Bioengineering (ENBENG), 2013 IEEE 3rd Portuguese Meeting in, Braga, Portugal (2013), pp. 1-3.
147. A. Bacon, J. Makin, P. J. Sizer, I. Jabbal-Gill, M. Hinchcliffe, L. Illum, S. Chatfield, and M. Roberts, Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun. 68, 5764 (2000).
148. M. Amidi, S. G. Romeijn, J. C. Verhoef, H. E. Junginger, L. Bungener, A. Huckriede, D. J. A. Crommelin, and W. Jiskoot, N -Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 25, 144 (2007).
149. S. M. Bal, B. Slütter, R. Verheul, J. A. Bouwstra, and W. Jiskoot, Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 45, 475 (2012).
150. R. C. Read, S. C. Naylor, C. W. Potter, J. Bond, I. Jabbal-Gill, A. Fisher, L. Illum, and R. Jennings, Effective nasal influenza vaccine delivery using chitosan. Vaccine 23, 4367 (2005).
151. A. Vila, A. Sánchez, K. Janes, I. Behrens, T. Kissel, J. L. V. Jato, and M. J. Alonso, Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57, 123 (2004).
152. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, a N. Fisher, and S. S. Davis, Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81 (2001).
153. P. Calvo, C. Remuñán-López, J. L. Vila-Jato, and M. J. Alonso, Chitosan and chitosan-ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14, 10 (1997).
154. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478 (2007).
155. J. L. Cleland, Single-administration vaccines: Controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 17, 25 (1999).
156. J. H. Eldridge, J. A. Meulbroek, J. K. Staas, T. R. Tice, and R. M. Gilley, Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv. Exp. Med. Biol. 251, 191 (1989).
157. P. L. Heritage, M. A. Brook, B. J. Underdown, and M. R. McDermott, Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 93, 249 (1998).
158. M. F. Bachmann and G. T. Jennings, Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787 (2010).
159. S. D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P. L. Mottram, and M. Plebanski, Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40, 1 (2006).
160. Y. J. Kwon, E. James, N. Shastri, and J. M. J. Fréchet, In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc. Natl. Acad. Sci. USA 102, 18264 (2005).
161. S. Flanary, A. S. Hoffman, and P. S. Stayton, Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug. Chem. 20, 241 (2009).
162. G. Minigo, A. Scholzen, C. K. Tang, J. C. Hanley, M. Kalkanidis, G. A. Pietersz, V. Apostolopoulos, and M. Plebanski, Poly-L-lysine-coated nanoparticles: A potent delivery system to enhance DNA vaccine efficacy. Vaccine 25, 1316 (2007).
163. S. Y. Seong, N. H. Cho, I. C. Kwon, and S. Y. Jeong, Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect. Immun. 67, 3587 (1999).
164. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice, Controlled vaccine release in the gutassociated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control Release 11, 205 (1990).
165. S. J. Challacombe, D. Rahman, H. Jeffery, S. S. Davis, and D. T. O'Hagan, Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76, 164 (1992).
166. K. G. Yeboah and M. J. D'souza, Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J. Microencapsul. 26, 166 (2009).
167. D. E. Katz, A. J. DeLorimier, M. K. Wolf, E. R. Hall, F. J. Cassels, J. E. van Hamont, R. L. Newcomer, M. A. Davachi, D. N. Taylor, and C. E. McQueen, Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21, 341 (2003).
168. F. Dobakhti, F. Rahimi, A. R. Dehpour, M. Taghikhani, S. Ajdary, S. Rafiei, and M. Rafiee-Tehrani, Stabilizing effects of calcium alginate microspheres on Mycobacterium bovis BCG intended for oral vaccination. J. Microencapsul. 23, 844 (2006).
169. L. Garcia-Contreras, Y.-L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W. A. Germishuizen, S. Goonesekera, K. Elbert, B. R. Bloom, R. Miller, P. B. Fourie, A. Hickey, and D. Edwards, Immunization by a bacterial aerosol. Proc. Natl. Acad. Sci. USA 105, 4656 (2008).
170. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M. F. Bachmann, Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404 (2008).
171. M. Look, A. Bandyopadhyay, J. S. Blum, and T. M. Fahmy, Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev. 62, 378 (2010).
172. G. Griffiths, B. Nyström, S. B. Sable, and G. K. Khuller, Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat. Rev. Microbiol. 8, 827 (2010).
173. B. C. Baudner and D. T. O'Hagan, Bioadhesive delivery systems for mucosal vaccine delivery. J. Drug Target. 18, 752 (2010).
174. H. O. Alpar, S. Somavarapu, K. N. Atuah, and V. W. Bramwell, Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411 (2005).
175. C. Lehr, J. Bouwstra, E. Schacht, and H. Junginger, In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78, 43 (1992).
176. J. Haas and C.-M. Lehr, Developments in the area of bioadhesive drug delivery systems. Expert Opin. Biol. Ther. 2, 287 (2002).
177. K. Leithner and A. Bernkop-Schnürch, Chitosan and derivatives for biopharmaceutical use: Mucoadhesive properties, Chitosan-Based Systems for Biopharmaceuticals, 1st ed., edited by B. Sarmento and J. Neves, 2012 John Wiley & Sons, Ltd., West Sussex, United Kingdom (2012), pp. 159-180.
178. E. A. McNeela, D. O'Connor, I. Jabbal-Gill, L. Illum, S. S. Davis, M. Pizza, S. Peppoloni, R. Rappuoli, and K. H. Mills, A mucosal vaccine against diphtheria: Formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19, 1188 (2000).
179. S. Channarong, W. Chaicumpa, N. Sinchaipanid, and A. Mitrevej, Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: The improvement of Peyer's patch targeting using a polyplex-loaded liposomes. AAPS PharmSciTech. 12, 192 (2011).
180. E. A. McNeela, I. Jabbal-Gill, L. Illum, M. Pizza, R. Rappuoli, A. Podda, D. J. M. Lewis, and K. H. G. Mills, Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: Enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22, 909 (2004).
181. B. C. Baudner, M. Morandi, M. M. Giuliani, J. C. Verhoef, H. E. Junginger, P. Costantino, R. Rappuoli, and G. Del Giudice, Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189, 828 (2004).
182. C. Porporatto, I. D. Bianco, and S. G. Correa, Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 78, 62 (2005).
183. H. Florindo, S. Pandit, L. Goncalves, H. O. Alpar, and A. J. Almeida, New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model. Vaccine 27, 1230 (2009).
184. A. Cadete, L. Figueiredo, R. Lopes, C. C. R. Calado, A. J. Almeida, and L. M. D. Gonçalves, Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles. Eur. J. Pharm. Sci. 45, 451 (2012).
185. L. Figueiredo, C. C. R. Calado, A. J. Almeida and L. M. D. Gonçalves, Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: In vivo evaluation, 2nd Portuguese Bio-Engineering Meeting 2012, I.I (2012), Vol. 1.
186. H. F. Florindo, S. Pandit, L. M. D. Gonçalves, M. Videira, O. Alpar, and A. J. Almeida, Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres. Biomaterials 30, 5161 (2009).
187. L. Figueiredo, A. Cadete, and L. M. D. Gonçalves, Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine 30, 6551 (2012).
188. M. A. Rodrigues, L. Figueiredo, L. Padrela, A. Cadete, J. Tiago, H. A. Matos, E. G. de Azevedo, H. F. Florindo, L. M. D. Gonçalves, and A. J. Almeida, Development of a novel mucosal vaccine against strangles by supercritical enhanced atomization spray-drying of Streptococcus equi extracts and evaluation in a mouse model. Eur. J. Pharm. Biopharm. 82, 392 (2012).
189. M. Han, S. Watarai, K. Kobayashi, and T. Yasuda, Application of liposomes for development of oral vaccines: Study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization. J. Vet. Med. Sci. 59, 1109 (1997).
190. M. E. Baca-Estrada, M. M. Foldvari, M. M. Snider, K. K. Harding, B. B. Kournikakis, L. A. Babiuk, and P. P. Griebel, Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18, 2203 (2000).
191. N. K. Childers, G. Tong, S. Mitchell, K. Kirk, M. W. Russell, and S. M. Michalek, A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect. Immun. 67, 618 (1999).
192. E. Harokopakis, G. Hajishengallis, and S. M. Michalek, Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immun. 66, 4299 (1998).
193. N. K. Childers, K. L. Miller, G. Tong, J. C. Llarena, T. Greenway, J. T. Ulrich, and S. M. Michalek, Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 68, 5509 (2000).
194. R. E. Smith, A. M. Donachie, and A. M. Mowat, Immune stimulating complexes as mucosal vaccines. Immunol. Cell Biol. 76, 263 (1998).
195. K. F. Hu, M. Elvander, M. Merza, L. Akerblom, A. Brandenburg, and B. Morein, The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol. 113, 235 (1998).
196. G. F. Rimmelzwaan, M. Baars, R. van Beek, G. van Amerongen, K. Lövgren-Bengtsson, E. C. Claas, and A. D. Osterhaus, Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and iscom vaccines. J. Gen. Virol. 78, 757 (1997).
197. A. M. Mowat, K. J. Maloy, and A. M. Donachie, Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 80, 527 (1993).
198. L. Chen, J. Wang, A. Zganiacz, and Z. Xing, Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72, 238 (2004).
199. M. Santosuosso, S. McCormick, X. Zhang, A. Zganiacz, and Z. Xing, Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74, 4634 (2006).
200. E. O. Ronan, L. N. Lee, E. Z. Tchilian, and P. C. L. Beverley, Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine. Vaccine 28, 5179 (2010).
201. T. M. Doherty, A. W. Olsen, L. Van Pinxteren, and P. Andersen, Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70, 3111 (2002).
202. J. Dietrich, R. Billeskov, T. M. Doherty, and P. Andersen, Synergistic effect of bacillus Calmette Guerin and a Tuberculosis subunit vaccine in cationic liposomes: Increased immunogenicity and protection. J. Immunol. 178, 3721 (2007).
203. M. Haile, B. Hamasur, T. Jaxmar, D. Gavier-Widen, M. A. Chambers, B. Sanchez, U. Schröder, G. Källenius, S. B. Svenson, and a Pawlowski, Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis 85, 107 (2005).
204. E. Stylianou, G. R. Diogo, I. Pepponi, C. van Dolleweerd, M. A. Arias, C. Locht, C. C. Rider, L. Sibley, S. M. Cutting, A. Loxley, J. K. C. Ma, and R. Reljic, Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur. J. Immunol. 44, 440 (2014).
205. M. J. Brennan, B. Clagett, H. Fitzgerald, V. Chen, A. Williams, A. A. Izzo, and L. F. Barker, Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 30, 2811 (2012).
206. Z. Xing and B. D. Lichty, Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis 86, 211 (2006).
207. T. Hawkridge and H. Mahomed, Prospects for a new, safer and more effective TB vaccine. Paediatr. Respir. Rev. 12, 46 (2011).
208. J. E. Eyles, G. J. Sharp, E. D. Williamson, I. D. Spiers, and H. O. Alpar, Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16, 698 (1998).
209. M. Lagranderie, P. Chavarot, A. M. Balazuc, and G. Marchal, Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18, 1186 (2000).
210. L. R. Ancelet, F. E. Aldwell, F. J. Rich, and J. R. Kirman, Oral vaccination with lipid-formulated BCG induces a long-lived, multifunctional CD4(+) T cell memory immune response. PLoS One 7, e45888 (2012).
211. S. Clark, M. L. Cross, A. Smith, P. Court, J. Vipond, A. Nadian, R. G. Hewinson, H. K. Batchelor, Y. Perrie, A. Williams, F. E. Aldwell, and M. A. Chambers, Assessment of different formulations of oral Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Vaccine 26, 5791 (2008).
212. F. E. Aldwell, M. L. Cross, C. E. Fitzpatrick, M. R. Lambeth, G. W. de Lisle, and B. M. Buddle, Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine 24, 2071 (2006).
213. B. Hamasur, M. Haile, A. Pawlowski, U. Schröder, A. Williams, G. Hatch, G. Hall, P. Marsh, G. Källenius, and S. B. Svenson, Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 21, 4081 (2003).
214. B. C. Baudner, M. M. Giuliani, J. C. Verhoef, R. Rappuoli, H. E. Junginger, and G. Del Giudice, The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21, 3837 (2003).
215. L. C. Freytag and J. D. Clements, Mucosal adjuvants. Vaccine 23, 1804 (2005).
216. C. A. S. Andersen, I. Rosenkrands, A. W. Olsen, P. Nordly, D. Christensen, R. Lang, C. Kirschning, J. M. Gomes, V. Bhowruth, D. E. Minnikin, G. S. Besra, F. Follmann, P. Andersen, and E. M. Agger, Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guérin. J. Immunol. 183, 2294 (2009).
217. E. K. Forbes, C. Sander, E. O. Ronan, A. V. S. Hill, P. C. L. Beverley, E. Z. Tchilian, and H. Mcshane, Multifuncional, high level cytoquine producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181, 4955 (2008).
218. C. A. Cosgrove, L. R. R. Castello-branco, T. Hussell, A. Sexton, R. Giemza, R. Phillips, A. Williams, G. E. Griffin, G. Dougan, and D. J. M. Lewis, Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect. Immun. 74, 2449 (2006).
219. F. E. Aldwell, D. L. Keen, N. A. Parlane, M. A. Skinner, G. W. de Lisle, and B. M. Buddle, Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine 22, 70 (2003).
220. B. M. Buddle, F. E. Aldwell, M. A. Skinner, G. W. de Lisle, M. Denis, H. M. Vordermeier, R. G. Hewinson, and D. N. Wedlock, Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis. Vaccine 23, 3581 (2005).
221. M. L. Cross, M. R. Lambeth, Y. Coughlan, and F. E. Aldwell, Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: Effect of reducing or eliminating BCG load on cell-mediated immunity. Vaccine 25, 1297 (2007).
222. M. Jeyanathan, A. Heriazon, and Z. Xing, Airway luminal T cells: A newcomer on the stage of TB vaccination strategies. Trends Immunol. 31, 247 (2010).
223. M. Jeyanathan, J. Mu, S. McCormick, D. Damjanovic, C.-L. Small, C. R. Shaler, K. Kugathasan, and Z. Xing, Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am. J. Respir. Crit. Care Med. 181, 862 (2010).
224. D. A. Hokey and A. Misra, Aerosol vaccines for tuberculosis: A fine line between protection and pathology. Tuberculosis 91, 82 (2010).
225. N. R. Labiris and M. B. Dolovich, Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 588 (2003).
226. E. Rytting, J. Nguyen, X. Wang, and T. Kissel, Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 5, 629 (2008).
227. M. Beck-Broichsitter, O. M. Merkel, and T. Kissel, Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J. Control Release 161, 214 (2012).
228. M. Bivas-Benita, T. H. M. Ottenhoff, H. E. Junginger, and G. Borchard, Pulmonary DNA vaccination: Concepts, possibilities and perspectives. J. Control Release 107, 1 (2005).
229. J. Kunisawa, S. Fukuyama, and H. Kiyono, Mucosa-associated lymphoid tissues in the aerodigestive tract: Their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr Mol Med 5, 557 (2005).